Shares of Epizyme, Inc. (EPZM) have traded between $8.81 – 25.46. The next earnings date is set for Feb 25, 2020. Let’s see how its prospects are shaping up.
What does Epizyme, Inc.(EPZM) do?
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
EPZM Insider Trading Insight
On 2019-06-27, Mott David M Dir sold 52,473 shares of EPZM. That represents a value of $4,430,794. Not to be outdone, on 2019-06-25, Mott David M S – Sale sold104,944 shares of EPZM. These insiders are clearly in the know because they work closely with the company.
The PSX Consensus Price Target
The mean recommendation of Phillips 66 from top Wall Street analysts is a Moderate Buy. That is based on 8 analysts who work on the Street. Based on 8 analysts offering 12 month price targets for Phillips 66 in the last 3 months. The average price target is $127.43 with a high forecast of $139.00 and a low forecast of $120.00. The average price target represents a 21.02% increase from the last price of $105.30. Last week, several articles were published in financial papers about PSX and 39% Bearish while 61% Bullish.
PSX Intraday Trading
PSX is due to report earnings on Jan 31, 2020. In the last year the price has ranged from 80.24 – 119.92. Recently, Herman Robert A sold 47,433 shares of PSX. He is a $55,462 shareholder in PSX.
Looking for stocks similar to EPZM and PSX?